CAR-NK’s balancing act: when scFv affinity is not too tight, not too loose… but just right?
Chimeric antigen receptor (CAR) therapies have revolutionized cancer treatment by enabling immune cells to target tumor cells with high specificity. While extensive research has focused on optimizing single-chain variable fragment (scFv) affinity in CAR-T cells, its impact on CAR-natural killer (NK)...
| Published in: | Journal for ImmunoTherapy of Cancer |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Online Access: | https://jitc.bmj.com/content/13/5/e012139.full |